FUJIFILM Biotechnologies, a top contract development and manufacturing company that focuses on biologics, vaccines, and advanced therapies, has announced it is expanding its global partnership with argenx SE, a well-known immunology company. As part of this new agreement, FUJIFILM Biotechnologies will start producing the drug substance for efgartigimod at its facility in Holly Springs, North Carolina, beginning in 2028. This move aligns with FUJIFILM Biotechnologies’ Phase II growth plan at the Holly Springs site, which will add eight 20,000-liter mammalian cell culture bioreactors to the existing eight reactors already on site.
Health Technology Insights: PVAMU Professor Honored for Advancing Nursing Leadership
Efgartigimod is a monoclonal antibody fragment specifically designed to target the neonatal Fc receptor, which is beneficial for patients suffering from severe autoimmune diseases. The drug is approved globally under the brand names VYVGART and VYVGART Hytrulo for treating adults with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Both of these conditions are chronic autoimmune neuromuscular disorders that cause significant muscle weakness.
With this expanded manufacturing agreement, argenx will benefit from FUJIFILM Biotechnologies’ kojoX network, a global modular system that offers localized supply and manufacturing close to patients. The kojoX network operates in several locations across the U.S., U.K., Denmark, and Japan, providing scalable clinical and commercial manufacturing capabilities that are tailored to meet customer needs.
Health Technology Insights: United Imaging Gains Record CE Marks in Medical AI
Lars Petersen, President and CEO of FUJIFILM Biotechnologies, shared that this collaboration represents their first comprehensive global program using the kojoX modular network. He explained that expanding manufacturing capacities in the U.S. will help meet argenx’s global supply chain needs for efgartigimod and emphasized the company’s commitment to supporting therapies that positively impact patients’ lives.
Filip Borgions, Chief Technology Innovation Officer at argenx, stated that the partnership strengthens their manufacturing presence in the U.S. and improves their global supply chain. He noted that the kojoX model ensures consistent capabilities across both the U.S. and Europe, allowing medications to be produced locally for American patients while supporting broader international distribution. Borgions expressed excitement about working with FUJIFILM Biotechnologies to fully benefit from the kojoX platform’s advantages.
Petersen also mentioned that the kojoX approach offers biopharmaceutical partners the flexibility and responsiveness needed to ensure supply chain stability and guarantee that patients around the world receive their essential treatments without any interruptions.
Health Technology Insights: Gold Coast Health Plan Earns NCQA Health Equity Accreditation
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
